Prognostic Value of D-Dimer in Patients with Diffuse Large B-cell Lymphoma: A Retrospective Study

Abstract

This study evaluated the significance of serum D-Dimer for predicting survival of patients with diffuse large B-cell lymphoma (DLBCL). We analyzed the clinical data from 113 patients who were newly diagnosed with DLBCL at Tongji Hospital from January 2012 to January 2016. The results indicated that there were higher levels of D-Dimer in DLBCL patients with the following characteristics: stage III/IV, lymphocyte monocyte ratio (LMR) <2.27, lactate dehydrogenase (LDH) > upper limit of normal (ULN), albumin (ALB) < 35 g/L, and anemia. After the first chemotherapeutic regimen, D-Dimer was significantly decreased concomitantly with LDH. Cox univariate regression analysis showed that the overall survival (OS) was negatively affected by the following factors: age > 60 years, stage III/W, LDH > ULN, LMR < 2.27, anemia and D-Dimer > 0.92. Multivariate analysis showed that only LDH > ULN (P=0.038) and age > 60 years (P=0.047) were independent adverse prognostic factors. However, it was suggested that D-Dimer could be regarded as a marker of high tumor burden and a potential prognostic screening tool for patients with DLBCL, not otherwise specified (NOS).

Keywords

diffuse large B-cell lymphoma / D-Dimer / prognosis

References

[1] CoiffierB, LepageE, BriereJ, et al.. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med, 2002, 346(4): 235-242

[2] MartelliM, FerreriAJ, AgostinelliC, et al.. Diffuse large B-cell lymphoma. Crit Rev Oncol Hematol, 2013, 87(2): 146-171

[3] SehnLH, BerryB, ChhanabhaiM, et al.. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood, 2007, 109(5): 1857-1861

[4] VaidyaR, WitzigTE. Prognostic factors for diffuse large B-cell lymphoma in the R(X)CHOP era. Ann Oncol, 2014, 25(11): 2124-2133

[5] ZhouZ, SehnLH, RademakerAW, et al.. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood, 2014, 123(6): 837-842

[6] TroppanKT, MelchardtT, DeutschA, et al.. The significance of pretreatment anemia in the era of R-IPI and NCCN-IPI prognostic risk assessment tools: a dual-center study in diffuse large B-cell lymphoma patients. Eur J Haematol, 2015, 95(6): 538-544

[7] FriedbergJW. New strategies in diffuse large B-cell lymphoma: translating findings from gene expression analyses into clinical practice. Clin Cancer Res, 2011, 17(19): 6112-6117

[8] HongJ, WooHS, KimH, et al.. Anemia as a useful biomarker in patients with diffuse large B-cell lymphoma treated with R-CHOP immunochemotherapy. Cancer Sci, 2014, 105(12): 1569-1575

[9] AdamsHJ, de KlerkJM, FijnheerR, et al.. Prognostic Value of Anemia and C-Reactive Protein Levels in Diffuse Large B-Cell Lymphoma. Clin Lymphoma Myeloma Leuk, 2015, 15(11): 671-679

[10] LiZM, HuangJJ, XiaY, et al.. Blood lymphocyte-to-monocyte ratio identifies high-risk patients in diffuse large B-cell lymphoma treated with R-CHOP. PLoS One, 2012, 7(7): e41658

[11] PorrataLF, RistowK, HabermannTM, et al.. Absolute monocyte/lymphocyte count prognostic score is independent of immunohistochemically determined cell of origin in predicting survival in diffuse large B-cell lymphoma. Leuk Lymphoma, 2012, 53(11): 2159-2165

[12] BaireyO, Shacham-AbulafiaA, ShpilbergO, et al.. Serum albumin level at diagnosis of diffuse large B-cell lymphoma: an important simple prognostic factor. Hematol Oncol, 2016, 34(4): 184-192

[13] DaliaS, ChavezJ, LittleB, et al.. Serum albumin retains independent prognostic significance in diffuse large B-cell lymphoma in the post-rituximab era. Ann Hematol, 2014, 93(8): 1305-1312

[14] GranOV, BraekkanSK, HansenJB. Prothrombotic genotypes and risk of venous thromboembolism in cancer. Thromb Res, 2018, 164(1): S12-S18

[15] PuurunenMK, EnserroD, XanthakisV, et al.. Biomarkers for the prediction of venous thromboembolism in the community. Thromb Res, 2016, 145: 34-39

[16] FronasSG, WikHS, DahmAEA, et al.. Safety of D-dimer testing as a stand-alone test for the exclusion of deep vein thrombosis as compared with other strategies. J Thromb Haemost, 2018, 16(12): 2471-2481

[17] EichingerS, HeinzeG, KyrlePA. D-dimer levels over time and the risk of recurrent venous thromboembolism: an update of the Vienna prediction model. J Am Heart Assoc, 2014, 3(1): e000467

[18] FengJF, YangX, ChenS, et al.. Prognostic Value of Plasma D-dimer in Patients with Resectable Esophageal Squamous Cell Carcinoma in China. J Cancer, 2016, 7(12): 1663-1667

[19] DeschA, GebhardtC, UtikalJ, et al.. D-dimers in malignant melanoma: Association with prognosis and dynamic variation in disease progress. Int J Cancer, 2017, 140(4): 914-921

[20] GengY, JianC, YangS, et al.. The Prognostic Value of D-Dimer in De Novo Acute Myeloid Leukemia. Am J Med Sci, 2016, 352(2): 129-133

[21] HarrisNL, JaffeES, DieboldJ, et al.. The World Health Organization classification of neoplastic diseases of the haematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997. Histopathology, 2000, 36(1): 69-86

[22] A predictive model for aggressive non-Hodgkin’s lymphoma.. The International Non-Hodgkin’s Lymphoma Prognostic Factors Project. N Engl J Med, 1993, 329(14): 987-994

[23] ScartozziM, GiampieriR, MaccaroniE, et al.. Pretreatment lactate dehydrogenase levels as predictor of efficacy of first-line bevacizumab-based therapy in metastatic colorectal cancer patients. Br J Cancer, 2012, 106(5): 799-804

[24] JungSH, YangDH, AhnJS, et al.. Serum lactate dehydrogenase with a systemic inflammation score is useful for predicting response and survival in patients with newly diagnosed diffuse large B-cell lymphoma. Acta Haematol, 2015, 133(1): 10-7

[25] GatenbyRA, GilliesRJ. Why do cancers have high aerobic glycolysis?. Nat Rev Cancer, 2004, 4(11): 891-899

[26] Abdol RazakNB, JonesG, BhandariM, et al.. Cancer-Associated Thrombosis: An Overview of Mechanisms, Risk Factors, and Treatment. Cancers (Basel), 2018, 10(10): 380

[27] ZanettoA, CampelloE, SpieziaL, et al.. Cancer-Associated Thrombosis in Cirrhotic Patients with Hepatocellular Carcinoma. Cancers (Basel), 2018, 10(11): E450 pii

[28] KilicL, YildizI, SenFK, et al.. D-dimer and international normalized ratio (INR) are correlated with tumor markers and disease stage in colorectal cancer patients. Cancer Biomark, 2015, 15(4): 405-411

[29] YamamotoM, YoshinagaK, MatsuyamaA, et al.. Plasma D-dimer level as a mortality predictor in patients with advanced or recurrent colorectal cancer. Oncology, 2012, 83(1): 10-5

[30] NishimuraK, OtaR, MikajiriY, et al.. Useful laboratory markers for the diagnosis of bone marrow involvement by malignant lymphoma. Int J Lab Hematol, 2018, 40(1): 34-40

[31] BorgIH, BendtsenMD, BogstedM, et al.. Incidence of venous thromboembolism in patients with diffuse large B-cell lymphoma. Leuk Lymphoma, 2016, 57(12): 2771-2776

[32] GadeIL, RiddersholmSJ, ChristiansenI, et al.. Venous thromboembolism in chronic lymphocytic leukemia: a Danish nationwide cohort study. Blood Adv, 2018, 2(21): 3025-3034

[33] LekovicD, MiljicP, MihaljevicB. Increased risk of venous thromboembolism in patients with primary mediastinal large B-cell lymphoma. Thromb Res, 2010, 126(6): 477-480

[34] LiuB, LiB, ZhouP, et al.. Prognostic value of pretreatment plasma D-dimer levels in patients with diffuse large B cell lymphoma (DLBCL). Clin Chim Acta, 2018, 482: 191-198

[35] WatanabeR, TomitaN, ItabashiM, et al.. Peripheral blood absolute lymphocyte/monocyte ratio as a useful prognostic factor in diffuse large B-cell lymphoma in the rituximab era. Eur J Haematol, 2014, 92(3): 204-210

[36] LiYL, GuKS, PanYY, et al.. Peripheral blood lymphocyte/monocyte ratio at the time of first relapse predicts outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma. BMC Cancer, 2014, 14: 341

[37] Yan-LiL, Kang-ShengG, Yue-YinP, et al.. The lower peripheral blood lymphocyte/monocyte ratio assessed during routine follow-up after standard first-line chemotherapy is a risk factor for predicting relapse in patients with diffuse large B-cell lymphoma. Leuk Res, 2014, 38(3): 323-328